InvestIdeas

What is happening ? I am lost with this company. Anybody follows this co. ?

Nope, i'm not following this Co.

My instant reaction is to ask if this company is the same as SinoBiopharma listed on nasdaq ...

From the chart pov, the stock is insane ... BO at 0.7, and closed at 2.61 today.

Congrats Stilicon, you must have made tons of $$$ ...

The biotech stocks i like are listed in nasdaq, henceforth i am not buying into the singapore/ china/ hk counters.

i think, there are a fair bit of mid-sized companies in the U.S. with good IPs, platform technology plus manufacturing process that is scaleable ...

Personally, i don't like commodities biotech businesses; i like biotech businesses in their unique space; especially, i like those biotech spin-offs which have subsequently matured into well-formed companies (yet still chunning decent product pipelines from the orginated universities) ... reverse innovation bah ...

Just my 2 cents.

Not vested

DJ MARKET TALK: Sino Biopharm +11.6% On China Life Stake Buy

1107 [Dow Jones] Sino Biopharmaceutical (1177.HK) last +11.6% at HK$2.50 on resuming trade; volume spikes to HK$606.5 million, making stock most heavily traded in HK, as includes shares placed.

Company announces it introduced China Life (2628.HK), funds under CITIC Securities as institutional investors, via issue of 255 million new shares at HK$2.10 each; says net proceeds of HK$533 million intended for acquisitions.

China Life earlier bought stake in Sino-Ocean Land (3377.HK), had similar boost to SOL share prices, but effect short-lived. China Life will only hold 4.2% stake in Sino Biopharm, strictly passive investor. Stock earlier surges 19.2% to HK$2.67, may cap short-term upside.

Source: Dow Jones Newswire

DJ MARKET TALK:DBS Raises Sino Biopharmaceutical Target To HK$3.2
December 11, 2009

1212 [Dow Jones] STOCK CALL: DBS raises target of Sino Biopharmaceutical (1177.HK) to HK$3.20 vs HK$2.23, with new target based on 1X PEG or 28X FY10 P/E, compared to previous 0.8X PEG, assuming its earnings visibility should improve following its decision to concentrate on its core business and expansion plan to capture growth opportunities created by new national medicine list.

"As a market leader with promising earnings growth outlook, SBP's valuation has strong potential to catch up with other first-tier peers like Shandong Weigao (8199.HK) and Sinopharm Group (1099.HK)." Sino Biopharmaceutical flat at HK$2.46


Source: Dow Jones Newswire

Not vested.

DJ MARKET TALK: Sino Biopharma Flags Sector Re-Rating Potential

1048 [Dow Jones] Sino Biopharmaceutical's (1177.HK) share price jump today on Morgan Stanley coverage initiation perhaps a signal of further re-rating potential of HK-listed drug stocks, which already up significantly year-to-date on expectations industry to benefit from China's healthcare reform, and such expectations backed by strong earnings growth.

Sino Biopharmaceutical last +13.1% at HK$3.63 after Morgan starts stock at Overweight with HK$5.00 target; stock now +47.6% year-to-date, vs HSI's 7.2% fall during same period.


Source: Dow Jones Newswire

Sino Biopharm (01177) places 185m shares to raise HK$603m

Dropped 7.6%, what else is in the news of pharmas? Most are in negative territory.

Sino Biopharmaceutical (01177) said it agreed to place 185 million existing shares at HK$3.35 apiece, to not less than 6 professional
investors.

The placing price represents a discount of 6.94% to the latest stock price of HK$3.6 per share.

The new shares represent 3.88% and 3.73% of the existing and enlarged issued share capital of the company.

The HK$603.06 million net proceeds will be applied to finance future possible acquisitions as and when appropriate opportunities arise.

Morgan Stanley and J.P. Morgan have agreed to act as the placing agents.

Source: ET Net News Agency

eauyong wrote:[b] Dropped 7.6%, what else is in the news of pharmas? Most are in negative territory.

Be careful. The regulators are trying to control the prices.

The difference can be about 100% from the manufacturer to the end-user.

They have so much $2.3B cash, why they still need to raise cash?